Enrofloxacin, a third-generation fluoroquinolone, is a broad-spectrum antimicrobial drug against a lot of veterinary bacterial diseases. However, bactericidal activity of enrofloxacin is concentration-dependent and its poor aqueous solubility and bitter taste limit its development and application. Meanwhile, 2-hydroxypropyl-β-cyclodextrin (HP-β-CD), a widely used cyclodextrin analog, is a safe and an effective drug carrier. It forms inclusion complexes with its drug substrates and improves their physiochemical and pharmacokinetic properties. Enrofloxacin was also found to form a stable inclusion complex with HP-β-CD and different research groups have shown improved solubility for enrofloxacin by 32.5%, 9.25 and 165-fold. Our own efforts in this direction resulted in manifold improvement (916-fold) in its solubility compared to the previous studies. It was further shown that pharmaceutical properties, absorption and bioavailability, of enrofloxacin have also been significantly improved by complexation with HP-β-CD.

中文翻译：

---

恩诺沙星与2-羟丙基-β-环糊精的包合物形成。

恩诺沙星（Enrofloxacin）是第三代氟喹诺酮，是一种针对许多兽医细菌疾病的广谱抗菌药物。然而，恩诺沙星的杀菌活性是浓度依赖性的，其不良的水溶性和苦味限制了其开发和应用。同时，广泛使用的环糊精类似物2-羟丙基-β-环糊精（HP-β-CD）是安全有效的药物载体。它与其药物底物形成包合物，并改善其理化和药代动力学特性。还发现恩诺沙星与HP-β-CD形成稳定的包合物，不同的研究小组显示对恩诺沙星的溶解度提高了32.5％，9.25和165倍。与以前的研究相比，我们在这个方向上的努力导致其溶解度得到了许多提高（916倍）。